参考文献:
1. 李彩和, 胡昌辰, 程东东,等. 非小细胞肺癌脑转移的靶向治疗进展[J]. 中国医院用药评价与分析, 2022, 22(4):7.
2. 刘晓晴,李治桦.EGFR基因突变NSCLC全程管理[J].医学与哲学(B),2014,35(11):15-19.
3. olomon BJ, et al. N Engl J Med. 2014 Dec 4;371(23):2167-77.
4. Zou Z, Xing P, Hao X, et al. Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases-a multicenter retrospective study. BMC Med. 2022;20(1):12.
5. Camidge DR. Lorlatinib Should Not be Considered as the Preferred First-Line Option in Patients With Advanced ALK Rearranged NSCLC [J]. J Thorac Oncol, 2021, 16(4):528-531.
6. Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. J Clin Oncol. 2020;38(31):3592-3603.
7. Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L .
8. MO Jahanzeb, et al. 2021 ESMO 1205P.